• go facebook
  • go twitter
  • go blog
  • go youtube
  • go linkedin
  • go rss

Date   :


Sort   :

move left
  • Parts & MaterialsAuto PartsShipbuilding & Offshore PlantsAerospaceICT
  • SemiconductorsDisplaysSpecialty ChemicalsBiopharmaceuticalNew & Renewable Energy
  • Logistics & DistributionFinanceTourism & LeisureCultural ContentReal Estate
  • FashionBeauty & CosmeticsFood & Beverage
move right


Based on innovation and competitiveness, Korea's biopharmaceutical industry continues to grow thanks to advancements in production infrastructure, support for entering overseas markets, and greater investemnt in R&D.

Korea's Biopharmaceutical Industry Trends (2011-2015)

  • Market Scale / Production Amount
韩国 45.8 31.7%
中国 19.2
新加坡 30.4

韩国 64.7 33.3%
中国 18.2
新加坡 33.1

韩国 56.0 33.7%
中国 16.7
新加坡 46.8

2014年 9月
韩国 61.9 30.4%
中国 15.2
新加坡 48.0
  • Exports / Imports
    第一 Hyundai Heavy Industries Co., Ltd.
第二 Samsung Heavy Industries Co., Ltd.

* Source: Ministry of Food and Drug Safety (2016)

Approval Status of New Drugs Developed in Korea (2015-2016)

By constatly expanding investment in R&D, Korea's biopharmaceutical industry has developed five new drugs in 2015 alone, and has received approval to develop 27 more as of December 2016.

국내 개발신약 허가 현황 (2015-2016)
Product Company Main Substance Efficay Approval Date
Acelex Cap. CrystalGenomics, Inc. Polmacoxib Osteoarthritis drug Feb. 2, 2015
Zabolante Tab. Dong-A ST Co., Ltd. Zabofloxacin
D-asparte hydrate
Antimicrobial (antibiotic) agent Mar.3, 2015
Sivextro Tab. Dong-A ST Co., Ltd. Tedizolid phosphate Antimicrobial (antibiotic) agent Apr. 17, 2015
Sivextro Inj.
Suganon Tab. Evogliptin tartrate antidiabetic drug Oct.2, 2015
Olita Tab. Hanmi Pharmaceutical Olmutinib HCL monohydrate Cancer drug (lung cancer) May 13, 2016


* Source: Ministry of Food and Drug Safety press release (2016)

Recommended Content

Industry Trends > Korea's Clinical Trial Industry in the Global Market


Success Stories > Merck Korea